Patents by Inventor Gennady N. Smagin

Gennady N. Smagin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDMA ENANTIOMERS
    Publication number: 20230310368
    Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.
    Type: Application
    Filed: June 8, 2023
    Publication date: October 5, 2023
    Applicant: Mind Medicine, Inc.
    Inventors: Robert BARROW, Daniel R. Karlin, Gennady N. Smagin
  • LIPOSOME DELIVERY OF PSYCHEDELICS
    Publication number: 20220354862
    Abstract: A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs. A method of treating a patient, by administering a composition of a psychedelic in a liposome formulation to the patient, and preferentially distributing the psychedelic at the CNS with a reduced exposure in target peripheral organs (e.g., heart).
    Type: Application
    Filed: April 29, 2022
    Publication date: November 10, 2022
    Applicant: Mind Medicine, Inc.
    Inventors: Robert BARROW, Gennady N. SMAGIN
  • Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
    Patent number: 10376506
    Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 13, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Connie Sanchez Morillo, Gennady N. Smagin
  • Use of an Opioid Receptor Antagonist with Kappa-Activity and Vortioxetine for Treatment of Depressive Disorder with Melancholic Features
    Publication number: 20160310488
    Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.
    Type: Application
    Filed: December 18, 2014
    Publication date: October 27, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Gennady N. Smagin